1218935-58-0

Basic information

• Product Name: (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate
• Synonyms: (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate
• CAS NO: 1218935-58-0
• Molecular Formula: C₁₅H₁₉F₂NO₂
• Molecular Weight: 283.3136664
• Mol File: 1218935-58-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate(1218935-58-0)
• EPA Substance Registry System: (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate(1218935-58-0)

Safety Data

• Hazardous Substances Data: 1218935-58-0(Hazardous Substances Data)

Usage

General Description

(R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate is a chemical compound with a molecular structure containing a pyrrolidine ring and a tert-butyl ester functional group. It is also known by the abbreviated name of (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate. (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate is a chiral molecule, meaning it has a non-superimposable mirror image, and the (R) prefix indicates that it has a specific stereochemical configuration. (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate may have potential applications in pharmaceutical research and organic chemistry due to its diverse structure and potential for interactions with biological systems. However, its specific uses and properties in these fields would depend on further research and testing.

Upstream product

• 399-94-0 2-bromo-1,4-difluorobenzene 
• 86953-79-9 tert-butyl pyrrolidine-1-carboxylate 
• 85909-08-6 tert-butyl 2-oxopyrrolidine-1-carboxylate 
• 899819-34-2 (2,5-difluorophenyl)magnesium bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1443623-92-4 5-(2,5-difluorophenyl)-3,4-dihydro-2H-pyrrole 

Downstream Products

• 1218935-60-4 (2R)-2-(2,5-difluorophenyl)pyrrolidine hydrochloride 
• 1218935-59-1 (R)-(+)-2-(2,5-difluorophenyl)pyrrolidine 
• 1260840-74-1 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-2,3-dihydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260846-28-3 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 
• 1260840-77-4 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260845-57-5 ethyl (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 1260842-01-0 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-2,3-dihydroxypropoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260846-92-1 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260845-56-4 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid 
• 1260840-05-8 (R)-N-tert-butyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260840-10-5 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(3-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 2135871-21-3 phenyl (5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate 
• 1223403-58-4 (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidi n-3-yl]-3-hydroxypyrrolidine-1-carboxamide 

Relevant articles and documents

Synthesis method of Larotrectinib intermediate and Larotrectinib

The invention discloses a synthesis method of Larotrectinib and a Larotrectinib intermediate. N-Boc pyrrolidone and 2,5-difluorophenyl magnesium bromide serve as raw materials, an intermediate A-1 isprepared, the intermediate A-1 is subjected to chiral catalysis hydrogenation, cyclization or first cyclization and afterwards chiral catalysis hydrogenation to obtain a chiral pyrrodlidine intermediate A-4, the intermediate A-4 and an intermediate B-3 are condensed to obtain an intermediate AB-1, the intermediate AB-1 is reduced to obtain an intermediate AB-2, the AB-2 is acylated to obtain an intermediate AB-3, and the AB-3 is subjected to a substitution reaction to obtain the target product Larotrectinib (AB-4). The intermediate A-4 with a high yield and high chiral purity is obtained through a chiral catalysis method, the B-3 with a high yield is obtained through a solvent-free one-pot method, and the Larotrectinib (AB-4) with a high yield and high purity is obtained. According to themethod, the reaction condition can also be applied to large-scale preparation, the method is suitable for industrial production, and therefore, the method has high practical values and social and economic benefits.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.